Medivir AB (MVRBF) Release: An All-Oral Phase 2a Study Combining Simeprevir, TMC647055 And JNJ56914845 In Hepatitis C Patients To Be Initiated
12/12/2013 9:49:54 AM
Stockholm, Sweden—Medivir AB (OMX: MVIR), announces the initiation of a phase
IIa trial in chronic genotype 1 hepatitis C infected patients to evaluate the
efficacy, safety and tolerability of a 12-week combination therapy of
simeprevir, TMC647055 and JNJ56914845, a NS5A replication complex inhibitor.
Help employers find you! Check out all the jobs and post your resume.
comments powered by